ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,629.00
0.55%
S&P ASX All Technology
3,016.30
1.48%
Brent Oil
82.765
0.00%
US Dollar vs AUD
1.514
0.00%
Bitcoin
63,426.29
-0.73%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Biogen Inc (0R1B)

  7. Biogen Inc (0R1B) News

0R1B Biogen Inc

277.67
0.00 (0.00%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Biogen Inc 0R1B London Ordinary Share
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
0.00 0.00% 277.67 10:00:00
Open Price Low Price High Price Close Price Previous Close
277.67 277.67
more quote information »

Recent News

Date Time Source Heading
26/4/202406:05GLOBEBiogen Receives Positive CHMP Opinion for TOFIDENCE™..
06/3/202423:30UKREGNew Biomarker Data Add Further Evidence Supporting the..
05/3/202408:15UKREGBiogen Highlights New Data at the International Conference..
23/2/202423:00UKREGBiogen’s QALSODY® (tofersen), the First Therapy to Treat..
13/2/202408:06UKREGBiogen Received European Commission Approval for SKYCLARYS®..
31/1/202423:30UKREGBiogen to Realign Resources for Alzheimer's Disease..
19/12/202323:30GLOBECentralized Marketing Authorizations of Generic Versions of..
16/12/202301:05GLOBECHMP Issues Positive Opinion for Biogen’s SKYCLARYS®..
14/12/202322:30GLOBEZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for..
06/11/202323:30GLOBEBiogen Appoints Monish Patolawala to its Board of Directors
26/10/202308:26GLOBEEisai Presents New LEQEMBI® (lecanemab-irmb) Investigational..
19/10/202322:30GLOBEBiogen to Present New Data at the Clinical Trials on..
26/9/202322:59GLOBEBiogen Completes Acquisition of Reata Pharmaceuticals
25/9/202315:02GLOBELEQEMBI® Intravenous Infusion (Lecanemab) Approved for the..
06/9/202321:30GLOBEBiogen Appoints Jane Grogan as Head of Research
07/8/202302:07ALNCNewsCORRECT: Biogens, Sage Therapeutics postpartum depression..
06/8/202323:17ALNCNewsBiogens, Sage Therapeutics postpartum depression treatment..
05/8/202312:41GLOBEFDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral..
28/7/202321:05GLOBEBiogen to Acquire Reata Pharmaceuticals
20/7/202309:30GLOBEEisai Presents Latest Analysis of Lecanemab’s Effect on..
07/7/202310:00GLOBEFDA Grants Traditional Approval for LEQEMBI®..
13/6/202307:14GLOBEBiogen Announces Changes to Its Board of Directors
10/6/202308:45GLOBEFDA Advisory Committee Votes Unanimously to Confirm the..
09/6/202321:12ALNCNews*Nasdaq halts trading of Biogen stock
16/5/202309:30GLOBEHealth Canada Accepts New Drug Submission for Lecanemab as..

Your Recent History

LSE
0R1B
Biogen
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved